UBS Group
AVBP icon

UBS Group’s ArriVent BioPharma AVBP Stock Holding History

UBS Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Sell
438,594
-47,669
-10% -$1.41M ﹤0.01% 2972
2026
Q1 		$11.2M Buy
486,263
+35,343
+8% +$798K ﹤0.01% 3206
2025
Q4 		$9.07M Sell
450,920
-46,681
-9% -$972K ﹤0.01% 3392
2025
Q3 		$9.18M Buy
497,601
+411,013
+475% +$8.08M ﹤0.01% 3388
2025
Q2 		$1.89M Sell
86,588
-115,597
-57% -$2.4M ﹤0.01% 4878
2025
Q1 		$3.74M Buy
202,185
+129,492
+178% +$3.17M ﹤0.01% 4076
2024
Q4 		$1.94M Buy
72,693
+54,057
+290% +$1.55M ﹤0.01% 4749
2024
Q3 		$438K Buy
18,636
+6,651
+55% +$151K ﹤0.01% 5324
2024
Q2 		$222K Buy
11,985
+2,090
+21% +$37.3K ﹤0.01% 5588
2024
Q1 		$177K Buy
+9,895
New +$200K ﹤0.01% 5942

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's AVBP Position: Q2 2026 in Review

UBS Group reduced its ArriVent BioPharma (AVBP) stake by 9.8% in Q2 2026, selling an estimated $1.41M and leaving 438,594 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

UBS Group first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • UBS Group held 438,594 shares of ArriVent BioPharma worth $15.2M as of Q2 2026.
  • UBS Group sold 47,669 ArriVent BioPharma shares in Q2 2026, an estimated $1.41M.
  • ArriVent BioPharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2972 holding.
  • UBS Group first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.